We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Breakthrough AI Tool Accurately Detects Pancreatic Cancer Using Non-Contrast CT Scans

By MedImaging International staff writers
Posted on 13 Dec 2023
Print article
Image: PANDA AI with enhanced non-contrast CT imaging could transform the detection of pancreatic cancer (Photo courtesy of media generated by DALL.E 3)
Image: PANDA AI with enhanced non-contrast CT imaging could transform the detection of pancreatic cancer (Photo courtesy of media generated by DALL.E 3)

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, accounts for nearly half a million deaths worldwide annually. Diagnosing this cancer at an early stage is notoriously difficult, as symptoms typically don't appear until the cancer has grown significantly and begun to spread. However, early detection can lead to potentially curative treatments, with up to 10% of early-diagnosed patients recovering fully after treatment. Now, a new AI-powered tool offers a breakthrough in detecting early signs of pancreatic cancer by enhancing and identifying subtle pathological features in standard CT scans.

This innovative AI platform, developed by DAMO Academy (Hangzhou, China), has been named PANDA (Pancreatic Cancer Detection with Artificial Intelligence). It demonstrates a remarkable capacity for identifying and classifying pancreatic lesions. PANDA employs deep learning algorithms to detect cancerous growths within the pancreas through non-contrast CT scans. This type of scan is globally preferred due to its lower radiation dose compared to contrast-enhanced scans. PANDA's initial training involved a dataset from 3,208 patients from a single medical center, making it a promising tool for early PDAC detection, potentially extending the median overall survival rate from approximately 1.5 years for late-stage cases to close to ten years for early detections.

In a comparative study, PANDA proved to be 34.1% more sensitive than human radiologists in identifying abnormalities from screening scans. The tool underwent validation in a real-world clinical environment, screening over 20,000 patients. During these screenings, PANDA identified pancreatic cancer-related pathological changes in 31 patients that were initially overlooked by doctors. Besides its heightened sensitivity, PANDA has been used clinically over 500,000 times, showing an impressively low false-positive rate of only one in every thousand tests, outperforming radiologists by 6.3%. This advanced AI tool holds the potential to revolutionize large-scale pancreatic cancer screening, possibly being incorporated into regular health check-ups or emergency department visits. Furthermore, researchers believe that PANDA might eventually be capable of detecting other cancer types as well.

“AI plus non-contrast CT technology hold the promise to be an effective and cost-efficient tool to achieve detection of pancreatic cancer in the early stages and make large-scale pancreatic cancer screening possible to prevent loss of lives,” said Le Lu, Head of Damo Academy’s medical AI team.

Related Links:
DAMO Academy

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
C-Arm with FPD
Digiscan V20 / V30
New
Wireless Handheld Ultrasound System
TE Air
New
Ultrasound Table
Powered Ultrasound Table-Flat Top

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.